Age, HIV & Metabolic Syndrome: Cognitive Decline Risk

Cognitive impairment is a growing concern for individuals living with HIV, and new research suggests that the interplay between age, HIV status, and metabolic syndrome significantly influences the risk. While aging naturally increases the likelihood of cognitive decline, the presence of HIV and metabolic syndrome appears to accelerate this process, particularly when these factors occur together.

The Interplay of Factors

A recent report highlighted at the Conference on Retroviruses and Infectious Diseases (CROI) in February 2026 indicates that individuals with HIV experience a steeper trajectory of cognitive impairment as they age compared to their HIV-negative counterparts. However, the study also revealed a crucial nuance: metabolic syndrome appears to exacerbate this decline in people living with HIV (PLWH). Notably, metabolic syndrome alone, without the presence of HIV, did not demonstrate a significant impact on cognitive impairment in individuals aged 65, and older.

Metabolic syndrome is a cluster of conditions – including high blood pressure, high blood sugar, abnormal cholesterol levels, and excess abdominal fat – that increase the risk of heart disease, stroke, and diabetes. It’s increasingly common in PLWH, often as a side effect of antiretroviral therapy, but also due to shared risk factors like inflammation and lifestyle.

HIV and Neurocognitive Impairment

The connection between HIV and neurocognitive impairment isn’t new. Research published in May 2019 in the Journal of Acquired Immune Deficiency Syndromes detailed the link between metabolic syndrome and neurocognitive deficits in HIV infection. The study, led by Beverly Yu and colleagues at Yale School of Medicine and the University of California San Diego, underscored that metabolic syndrome is a frequent comorbidity in individuals with HIV and has been associated with increased neurocognitive impairment even in the general population.

As PLWH age, they become susceptible to impairments in everyday function due to physiological and psychosocial stressors. Interactions between HIV and age-related neurodegeneration can further increase the risk of difficulties with medication management, as noted in research published in August 2023 in the Journal of Alzheimer’s Disease. This highlights the importance of addressing cognitive health in aging PLWH.

Racial and Ethnic Disparities

Recent findings also point to potential disparities in neurocognitive function among different racial and ethnic groups. A study published in June 2024 revealed that Hispanic patients with HIV aged 50 and older exhibited significantly worse global neurocognition, as well as lower scores in learning, memory, and visual-spatial skills, compared to their non-Hispanic White counterparts. This study also found a higher prevalence of metabolic syndrome among Hispanic patients, suggesting a potential link between ethnicity, metabolic health, and cognitive function in this population.

Specifically, the research indicated that Hispanic patients had a more than twofold higher odds of having metabolic syndrome compared to non-Hispanic White patients (odds ratio, 2.13; 95% CI, 1.01-4.53; P <.05).

Implications for Clinical Practice

These findings underscore the need for comprehensive and proactive management of metabolic syndrome in PLWH, particularly as they age. Early detection and intervention – including lifestyle modifications, such as diet and exercise, and appropriate medical management of conditions like hypertension and diabetes – may help mitigate the risk of cognitive decline.

The research also emphasizes the importance of considering racial and ethnic factors when assessing and addressing neurocognitive health in PLWH. Culturally sensitive approaches and targeted interventions may be necessary to address disparities and ensure equitable access to care.

While the exact mechanisms underlying the link between HIV, metabolic syndrome, and cognitive impairment are still being investigated, the evidence suggests a complex interplay of factors, including inflammation, vascular damage, and neuronal dysfunction. Further research is needed to fully elucidate these mechanisms and develop effective strategies to prevent and treat neurocognitive decline in aging PLWH.

The National Institute on Aging continues to support advances in aging and Alzheimer’s research, which may ultimately benefit PLWH as well. Ongoing studies are exploring potential biomarkers for early detection of cognitive impairment and evaluating the efficacy of novel therapeutic interventions.